Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Web-based Study of Darbepoetin Alfa in Anemic Cancer Patients
NCT00153868Phase 4Completed
- Sponsor
- Dartmouth Health
- Start
- Oct 2003
- Primary completion
- Aug 2007
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 4, open-label trial of darbepoetin alfa in anemia (2 arms), sponsored by Dartmouth Health. Primary endpoints: Lung Cancer Symptom Scale at 13 weeks, Short Form-36 at 13 weeks and 2 more. Started Oct 2003; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00153868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153868.